Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells.


Journal

Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097

Informations de publication

Date de publication:
01 Sep 2020
Historique:
pubmed: 8 4 2020
medline: 29 10 2020
entrez: 8 4 2020
Statut: ppublish

Résumé

The deubiquitinase cylindromatosis (CYLD) functions as a tumor suppressor inhibiting cell proliferation in many cancer types including melanoma. Here we present evidence that a proportion of melanoma cells are nonetheless addicted to CYLD for survival. The expression levels of CYLD varied widely in melanoma cell lines and melanomas in vivo, with a subset of melanoma cell lines and melanomas displaying even higher levels of CYLD than melanocyte lines and nevi, respectively. Strikingly, although short hairpin RNA (shRNA) knockdown of CYLD promoted, as anticipated, cell proliferation in some melanoma cell lines, it reduced cell viability in a fraction of melanoma cell lines with relatively high levels of CYLD expression and did not impinge on survival and proliferation in a third type of melanoma cell lines. The decrease in cell viability caused by CYLD knockdown was due to induction of apoptosis, as it was associated with activation of the caspase cascade and was abolished by treatment with a general caspase inhibitor. Mechanistic investigations demonstrated that induction of apoptosis by CYLD knockdown was caused by upregulation of receptor-interacting protein kinase 1 (RIPK1) that was associated with elevated K63-linked polyubiquitination of the protein, indicating that CYLD is critical for controlling RIPK1 expression in these cells. Of note, microRNA (miR) profiling showed that miR-99b-3p that was predicted to target the 3-untranslated region (3-UTR) of the CYLD mRNA was reduced in melanoma cell lines with high levels of CYLD compared with melanocyte lines. Further functional studies confirmed that the reduction in miR-99b-3p expression was responsible for the increased expression of CYLD in a highly cell line-specific manner. Taken together, these results reveal an unexpected role of CYLD in promoting survival of a subset of melanoma cells and uncover the heterogeneity of CYLD expression and its biological significance in melanoma.

Identifiants

pubmed: 32252875
doi: 10.3727/096504020X15861709922491
pmc: PMC7851542
doi:

Substances chimiques

3' Untranslated Regions 0
MicroRNAs 0
RNA, Messenger 0
RNA, Small Interfering 0
RIPK1 protein, human EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinases EC 2.7.11.1
CYLD protein, human EC 3.4.19.12
Deubiquitinating Enzyme CYLD EC 3.4.19.12

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

385-398

Références

Cell Death Differ. 2016 Aug;23(8):1394-405
pubmed: 27258785
Cell Death Dis. 2018 Jun 7;9(6):679
pubmed: 29880840
Cancer. 2017 May 15;123(10):1778-1790
pubmed: 28295222
J Exp Med. 2009 Jan 16;206(1):221-32
pubmed: 19124656
Cancer Res. 2017 Nov 15;77(22):6226-6239
pubmed: 28947420
Oncotarget. 2015 Nov 24;6(37):39891-907
pubmed: 26573229
Exp Dermatol. 2016 Jul;25(7):497-500
pubmed: 27060971
Transl Oncol. 2017 Dec;10(6):956-975
pubmed: 29078205
Nat Rev Mol Cell Biol. 2005 Aug;6(8):599-609
pubmed: 16064136
J Biol Chem. 2011 Jun 17;286(24):21546-54
pubmed: 21525013
Nat Immunol. 2011 Nov 06;12(12):1176-83
pubmed: 22057290
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15840-5
pubmed: 21896753
J Biol Chem. 2004 Aug 27;279(35):36171-4
pubmed: 15226292
Nucleic Acids Res. 2016 May 5;44(8):3865-77
pubmed: 26921406
Oncogene. 2018 Jul;37(29):4033-4045
pubmed: 29706658
Cell Rep. 2017 Nov 14;21(7):1953-1967
pubmed: 29141225
Nat Med. 2018 Feb;24(2):203-212
pubmed: 29334371
Biomed Res Int. 2018 Apr 2;2018:2086564
pubmed: 29808164
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
JAMA Oncol. 2016 Oct 1;2(10):1259-1260
pubmed: 27561103
Cancer Cell. 2019 Feb 11;35(2):238-255.e6
pubmed: 30753825
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):313-322
pubmed: 30776401
Nature. 2003 Aug 14;424(6950):801-5
pubmed: 12917691
Nat Genet. 2000 Jun;25(2):160-5
pubmed: 10835629
Cancer Res. 2015 Apr 15;75(8):1736-48
pubmed: 25724678
Annu Rev Cell Dev Biol. 2006;22:159-80
pubmed: 16753028
Curr Drug Targets. 2015;16(4):284-94
pubmed: 25342597
Nat Commun. 2019 Apr 15;10(1):1729
pubmed: 30988283
Cell Death Differ. 2017 Jul;24(7):1172-1183
pubmed: 28362430
J Invest Dermatol. 2013 Jan;133(1):221-9
pubmed: 22832488
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270
pubmed: 29127120
Oncogene. 2014 May 15;33(20):2577-88
pubmed: 23770856
Pigment Cell Melanoma Res. 2017 Mar;30(2):233-242
pubmed: 28002643
Cell. 2008 May 16;133(4):693-703
pubmed: 18485876
RNA Biol. 2016 Nov;13(11):1084-1088
pubmed: 27687236
Dev Cell. 2007 Nov;13(5):705-16
pubmed: 17981138
Nature. 2003 Aug 14;424(6950):793-6
pubmed: 12917689
Cancer Res. 2008 Aug 15;68(16):6708-17
pubmed: 18701495
Mol Cell. 2017 Jun 1;66(5):698-710.e5
pubmed: 28506461
Cancer Res. 2018 Dec 1;78(23):6666-6679
pubmed: 30301840
J Biol Chem. 2011 Apr 15;286(15):13282-91
pubmed: 21339290
Nat Commun. 2017 Jan 18;8:14121
pubmed: 28098136
Eur J Med Genet. 2015 May;58(5):271-8
pubmed: 25782638
Future Oncol. 2011 Feb;7(2):285-97
pubmed: 21345146
Nat Commun. 2018 Jul 10;9(1):2665
pubmed: 29991680
Int J Cancer. 2019 Aug 15;145(4):974-978
pubmed: 30694555
Mol Cell Biol. 2002 Sep;22(17):6034-45
pubmed: 12167698
Gene. 2018 Jan 30;641:272-278
pubmed: 29054757
Cell Death Differ. 2010 Jan;17(1):25-34
pubmed: 19373246
Mol Cell. 2011 Aug 5;43(3):432-48
pubmed: 21737329
Cell. 2009 May 15;137(4):721-35
pubmed: 19427028
Trends Pharmacol Sci. 2017 Mar;38(3):202-225
pubmed: 28126382
Cell. 2006 May 19;125(4):665-77
pubmed: 16713561
Mol Cell. 2008 Jun 20;30(6):689-700
pubmed: 18570872
Mol Cell Oncol. 2015 May 26;3(1):e1035690
pubmed: 27308554
Wiley Interdiscip Rev RNA. 2012 May-Jun;3(3):311-30
pubmed: 22072587
NPJ Genom Med. 2017;2:
pubmed: 28819565
Int J Genomics. 2014;2014:970607
pubmed: 25180174
Nature. 2003 Aug 14;424(6950):797-801
pubmed: 12917690
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Oncol Lett. 2016 Oct;12(4):2301-2306
pubmed: 27698793
Nat Commun. 2013;4:1508
pubmed: 23443536
Clin Cancer Res. 2001 Mar;7(3 Suppl):966s-973s
pubmed: 11300498
Int J Oncol. 2012 Jul;41(1):53-60
pubmed: 22469839

Auteurs

Ting La (T)

Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.

Lei Jin (L)

Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.

Xiao Ying Liu (XY)

Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.

Ze Hua Song (ZH)

Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.

Margaret Farrelly (M)

School of Biomedical Sciences and Pharmacy, The University of NewcastleCallaghan, NSWAustralia.

Yu Chen Feng (YC)

School of Biomedical Sciences and Pharmacy, The University of NewcastleCallaghan, NSWAustralia.

Xu Guang Yan (XG)

School of Biomedical Sciences and Pharmacy, The University of NewcastleCallaghan, NSWAustralia.

Yuan Yuan Zhang (YY)

School of Biomedical Sciences and Pharmacy, The University of NewcastleCallaghan, NSWAustralia.

Rick F Thorne (RF)

Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.

Xu Dong Zhang (XD)

Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.

Liu Teng (L)

Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH